| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/04/2004 | EP1442061A1 Reducing immunogenicities of immunoglobulins by framework-patching |
| 08/04/2004 | EP1442060A2 A novel g protein-coupled receptor, gave 10 |
| 08/04/2004 | EP1442052A1 High level constitutive production of anthrax protective antigen |
| 08/04/2004 | EP1442047A2 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 08/04/2004 | EP1442046A2 Mammalian c-type lectins |
| 08/04/2004 | EP1441766A2 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| 08/04/2004 | EP1441765A2 Method for preparation of single chain antibodies |
| 08/04/2004 | EP1441764A2 Antigen arrays comprising rankl for treatment of bone disease |
| 08/04/2004 | EP1441763A2 Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
| 08/04/2004 | EP1441762A1 Rsv gene expression vaccine |
| 08/04/2004 | EP1441761A2 Methods of preventing and treating flavivirus infection in animals |
| 08/04/2004 | EP1441760A2 Anthrax antigenic compositions |
| 08/04/2004 | EP1441759A2 Cellular vaccines comprising adjuvants |
| 08/04/2004 | EP1441758A2 Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell |
| 08/04/2004 | EP1441752A1 Endophilin homologous proteins involved in the regulation of energy homeostasis |
| 08/04/2004 | EP1441748A2 High-concentration protein formulations and method of manufacture |
| 08/04/2004 | EP1441743A2 Methods for treating ocular neovascular diseases |
| 08/04/2004 | EP1441735A1 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| 08/04/2004 | EP1441684A2 Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524 |
| 08/04/2004 | EP1441661A1 Method and tools for oral hygiene |
| 08/04/2004 | EP1441589A2 Stable liquid pharmaceutical formulation of igg antibodies |
| 08/04/2004 | EP1313772B1 New cross-linked derivatives of hyaluronic acid |
| 08/04/2004 | EP1165600B1 Proteins modified by xanthurenic acid |
| 08/04/2004 | EP1165140B1 Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines |
| 08/04/2004 | EP1034001B1 Cd154 blockade therapy for therapeutic protein inhibitor syndrome |
| 08/04/2004 | EP1029246B1 A method and device for preventing immunoglobulin degradation in external secretions |
| 08/04/2004 | EP0951299B1 Method of producing active immunity with vaccine conjugate |
| 08/04/2004 | EP0790835B1 Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| 08/04/2004 | EP0764171B1 Ligands for induction of antigen specific apoptosis in t cells |
| 08/04/2004 | EP0637963B1 Cd28 pathway immunoregulation |
| 08/04/2004 | EP0480949B2 Production of viral vaccine |
| 08/04/2004 | CN1518598A Serpin in Bifidobacteria |
| 08/04/2004 | CN1518559A VHH single heavy chain antibody and method for its preparation in mammal |
| 08/04/2004 | CN1518558A Peptides and/or proteins and use thereof for production of therapeutic and/or prophylactic medicament |
| 08/04/2004 | CN1518458A Graft rejection inhibitors |
| 08/04/2004 | CN1518457A Methods of inducing cytotoxic immune response and recombinant simian ademovirus compositions useful therein |
| 08/04/2004 | CN1518456A Capsular polysaccharide solubilisation and combination vaccines |
| 08/04/2004 | CN1517437A Vaccine for specificity treating tumour or endocellular infection and application |
| 08/04/2004 | CN1160469C Identification of genes |
| 08/04/2004 | CN1160462C Use of gram-positive bacteria to express recombinant proteins |
| 08/04/2004 | CN1160457C Recombinant mistletoe lectin (rML) |
| 08/04/2004 | CN1160454C Enhanced immunogen for inactivated vaccine for infection with Japanese ence phalitis viruses and process for producing the same |
| 08/04/2004 | CN1160371C NOTCH protein and their ligands |
| 08/04/2004 | CN1160125C Immune anticaries DNA vaccine, preparing method and use thereof |
| 08/04/2004 | CN1160124C Process for preparing bacterial vaccine for aquiculture animal |
| 08/04/2004 | CN1160116C Specific immunological inhibitor |
| 08/03/2004 | US6770797 Inducing prolonged in vivo gene expression in a mammal for inhibiting alzheimer's disease associated neuronal cell death |
| 08/03/2004 | US6770749 Nucleic acids coding for both a and b chains of human p53, human leukocyte antigen(hla) restricted murine t-cell receptor (tcr); transformed cd8+ cytotoxic t lymphocytes for immunotherapy of tumors that over-express p53 |
| 08/03/2004 | US6770745 Common gamma chain blocking agents |
| 08/03/2004 | US6770743 Genetic engineered drug |
| 08/03/2004 | US6770456 Endogenous retrovirus tumor associated nucleic acids and antigens |
| 08/03/2004 | US6770438 Oncogene, oncoprotein; associated with tumorigenicity; mn genes from cellular component of matu, a quasi viral agent derived from a human mammary tumor |
| 08/03/2004 | US6770284 Polypeptides and polynucleotides BASB040 from neisseria meningitidis and vaccine comprising said polypeptides and polynucleotides |
| 08/03/2004 | US6770283 DNA expression systems based on alphaviruses |
| 08/03/2004 | US6770282 Purified nucleic acid molecule encoding rabies glycoprotein g, complexed with a cationic lipid comprising tetramethyltetraalkyl spermine analog lipid; enhances immune response compared to administration of a naked dna vaccine |
| 08/03/2004 | US6770281 B-cell epitope peptides of HSP 65 |
| 08/03/2004 | US6770279 TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis |
| 08/03/2004 | US6770275 Isolated live, attenuated apx toxin-producing actinobacillus pleuropneumoniae having a deletion in two apx activator genes wherein does not produce two functional apx activator proteins, but two apx toxins in a non-activated form |
| 08/03/2004 | US6770273 Vaccine based on attenuated Haemophilus somnus |
| 08/03/2004 | US6770260 Mammal model contains a decreased level of endogenous macrophages sufficient to reduce depletion of non-autologous hematopoietic cells, achieved by administering an effective amount of dichloromethylene diphosphonate |
| 08/03/2004 | CA2160696C Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus |
| 08/03/2004 | CA2144317C Hepatitis a virus vaccines |
| 08/03/2004 | CA2041093C A pharmacological composition containing polyelectrolyte complexes in microparticulate form and at least one active substance |
| 07/29/2004 | WO2004063342A2 Cellular delivery and activation polypeptide-nucleic acid complexes |
| 07/29/2004 | WO2004063217A1 Dimerized peptide |
| 07/29/2004 | WO2004062690A1 Novel method for isolating endotoxins |
| 07/29/2004 | WO2004062651A1 Pharmaceutical aerosol composition |
| 07/29/2004 | WO2004062619A2 SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF |
| 07/29/2004 | WO2004062603A2 Methods of treating lung diseases |
| 07/29/2004 | WO2004062597A2 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector |
| 07/29/2004 | WO2004062584A2 Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection |
| 07/29/2004 | WO2004062583A2 Vaccine and method for preventing biofilm formation |
| 07/29/2004 | WO2004062578A2 Methods for reducing mortality associated with acute myocardial infarction |
| 07/29/2004 | WO2004062567A2 Arterivirus marker vaccine |
| 07/29/2004 | WO2004062560A2 Pharmaceutical composition |
| 07/29/2004 | WO2004062559A2 Use of microcapsules comprising an antigen for the manufacture of an ex-vivo medicament to initiate an immune response |
| 07/29/2004 | WO2004062551A2 RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
| 07/29/2004 | WO2004050111A3 Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment |
| 07/29/2004 | WO2004048402A3 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene |
| 07/29/2004 | WO2004037856A3 Plasmodium falciparum virulence factor var o |
| 07/29/2004 | WO2004037175A3 Compositions and methods for treating human papillomavirus-mediated disease |
| 07/29/2004 | WO2004035536A3 Azo compounds for type i phototherapy |
| 07/29/2004 | WO2004024889A3 Production of bispecific molecules using polyethylene glycol linkers |
| 07/29/2004 | WO2004021772A8 Immune cloning and uses thereof |
| 07/29/2004 | WO2004019910A3 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| 07/29/2004 | WO2004019764A3 'diagnosis and treatment of infertility' |
| 07/29/2004 | WO2004000873A3 Adjuvant-free peptide vaccine |
| 07/29/2004 | WO2003098212B1 Method of isolating an endotehelial cell and method of donor specific crossmatching |
| 07/29/2004 | WO2003094850A3 Lipid a and other carbohydrate ligand analogs |
| 07/29/2004 | WO2003093313A3 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
| 07/29/2004 | WO2003077838A3 Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens |
| 07/29/2004 | WO2003075741A3 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
| 07/29/2004 | WO2003066833A3 Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies |
| 07/29/2004 | WO2003059951A8 Novel anti-igf-ir antibodies and uses thereof |
| 07/29/2004 | WO2003033644A3 Peptide useful in immunomodulation |
| 07/29/2004 | WO2003028634A8 Method of treatment using ligand-immunogen conjugates |
| 07/29/2004 | WO2003018623A3 Papillomavirus proteins and pharmaceutical compositions |
| 07/29/2004 | WO2003003941A3 One dose vaccination with mycoplasma hyopneumoniae |
| 07/29/2004 | WO2002094994A3 Chimeric antigen-specific t cell-activating polypeptides |
| 07/29/2004 | US20040147739 Novel anti-infectives |